NY-ESO-1 Protein Cancer Vaccine with Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC

Tomohira Takeoka, Hirotsugu Nagase, Koji Kurose, Yoshihiro Ohue, Makoto Yamasaki, Shuji Takiguchi, Eiichi Sato, Midori Isobe, Takayuki Kanazawa, Mitsunobu Matsumoto, Kota Iwahori, Atsunari Kawashima, Akiko Morimoto-Okazawa, Hiroyoshi Nishikawa, Mikio Oka, Linda Pan, Ralph Venhaus, Eiichi Nakayama, Masaki Mori, Yuichiro DokiHisashi Wada

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We conducted a clinical trial of a cancer vaccine using NY-ESO-1 protein with polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose (poly-ICLC) and/or OK-432 against solid tumors. A total of 15 patients were sequentially enrolled in 4 cohorts. Patients in cohort 1 received NY-ESO-1 protein; cohort 2a received NY-ESO-1 protein+OK-432; cohort 2b received NY-ESO-1 protein+poly-ICLC; cohort 3 received NY-ESO-1 protein+OK-432+poly-ICLC with Montanide ISA-51. The endpoints of this trial were safety, NY-ESO-1 immune responses, and clinical response. Vaccine-related adverse events observed were fever and injection-site reaction (grade 1). Two patients showed stable disease after vaccination. NY-ESO-1 antibodies were observed in 4 patients at the baseline (sero-positive) and augmented in all patients after vaccination. Eleven patients showed a conversion of negative antibody responses at baseline to positive after vaccination (seroconversion). The seroconversions were observed in all 11 sero-negative patients by the fourth immunization; in particular, it was observed by the second immunization in patients with poly-ICLC, and these induced antibody responses were stronger than those in patients immunized without poly-ICLC. The number of NY-ESO-1-specific interferon (IFN)γ-producing T cells was increased in patients immunized with poly-ICLC and/or OK-432, and furthermore, the increase of IFNγ-producing CD8 T cells in patients immunized with poly-ICLC was significantly higher than that in patients without poly-ICLC. Nonspecific activations of T-cell or antigen presenting cells were not observed. Our present study showed that poly-ICLC is a promising adjuvant for cancer vaccines.

Original languageEnglish
Pages (from-to)140-147
Number of pages8
JournalJournal of Immunotherapy
Volume40
Issue number4
DOIs
Publication statusPublished - Jan 1 2017
Externally publishedYes

Fingerprint

Picibanil
Cancer Vaccines
Carboxymethylcellulose Sodium
Lysine
Proteins
Vaccination
T-Lymphocytes
Interferons
Antibody Formation
poly ICLC
Immunization
Poly I-C
Viral Tumor Antigens
Antigen-Presenting Cells

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this

NY-ESO-1 Protein Cancer Vaccine with Poly-ICLC and OK-432 : Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC. / Takeoka, Tomohira; Nagase, Hirotsugu; Kurose, Koji; Ohue, Yoshihiro; Yamasaki, Makoto; Takiguchi, Shuji; Sato, Eiichi; Isobe, Midori; Kanazawa, Takayuki; Matsumoto, Mitsunobu; Iwahori, Kota; Kawashima, Atsunari; Morimoto-Okazawa, Akiko; Nishikawa, Hiroyoshi; Oka, Mikio; Pan, Linda; Venhaus, Ralph; Nakayama, Eiichi; Mori, Masaki; Doki, Yuichiro; Wada, Hisashi.

In: Journal of Immunotherapy, Vol. 40, No. 4, 01.01.2017, p. 140-147.

Research output: Contribution to journalArticle

Takeoka, T, Nagase, H, Kurose, K, Ohue, Y, Yamasaki, M, Takiguchi, S, Sato, E, Isobe, M, Kanazawa, T, Matsumoto, M, Iwahori, K, Kawashima, A, Morimoto-Okazawa, A, Nishikawa, H, Oka, M, Pan, L, Venhaus, R, Nakayama, E, Mori, M, Doki, Y & Wada, H 2017, 'NY-ESO-1 Protein Cancer Vaccine with Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC', Journal of Immunotherapy, vol. 40, no. 4, pp. 140-147. https://doi.org/10.1097/CJI.0000000000000162
Takeoka, Tomohira ; Nagase, Hirotsugu ; Kurose, Koji ; Ohue, Yoshihiro ; Yamasaki, Makoto ; Takiguchi, Shuji ; Sato, Eiichi ; Isobe, Midori ; Kanazawa, Takayuki ; Matsumoto, Mitsunobu ; Iwahori, Kota ; Kawashima, Atsunari ; Morimoto-Okazawa, Akiko ; Nishikawa, Hiroyoshi ; Oka, Mikio ; Pan, Linda ; Venhaus, Ralph ; Nakayama, Eiichi ; Mori, Masaki ; Doki, Yuichiro ; Wada, Hisashi. / NY-ESO-1 Protein Cancer Vaccine with Poly-ICLC and OK-432 : Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC. In: Journal of Immunotherapy. 2017 ; Vol. 40, No. 4. pp. 140-147.
@article{8c482be25aad4168aaa62b29480b3702,
title = "NY-ESO-1 Protein Cancer Vaccine with Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC",
abstract = "We conducted a clinical trial of a cancer vaccine using NY-ESO-1 protein with polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose (poly-ICLC) and/or OK-432 against solid tumors. A total of 15 patients were sequentially enrolled in 4 cohorts. Patients in cohort 1 received NY-ESO-1 protein; cohort 2a received NY-ESO-1 protein+OK-432; cohort 2b received NY-ESO-1 protein+poly-ICLC; cohort 3 received NY-ESO-1 protein+OK-432+poly-ICLC with Montanide ISA-51. The endpoints of this trial were safety, NY-ESO-1 immune responses, and clinical response. Vaccine-related adverse events observed were fever and injection-site reaction (grade 1). Two patients showed stable disease after vaccination. NY-ESO-1 antibodies were observed in 4 patients at the baseline (sero-positive) and augmented in all patients after vaccination. Eleven patients showed a conversion of negative antibody responses at baseline to positive after vaccination (seroconversion). The seroconversions were observed in all 11 sero-negative patients by the fourth immunization; in particular, it was observed by the second immunization in patients with poly-ICLC, and these induced antibody responses were stronger than those in patients immunized without poly-ICLC. The number of NY-ESO-1-specific interferon (IFN)γ-producing T cells was increased in patients immunized with poly-ICLC and/or OK-432, and furthermore, the increase of IFNγ-producing CD8 T cells in patients immunized with poly-ICLC was significantly higher than that in patients without poly-ICLC. Nonspecific activations of T-cell or antigen presenting cells were not observed. Our present study showed that poly-ICLC is a promising adjuvant for cancer vaccines.",
author = "Tomohira Takeoka and Hirotsugu Nagase and Koji Kurose and Yoshihiro Ohue and Makoto Yamasaki and Shuji Takiguchi and Eiichi Sato and Midori Isobe and Takayuki Kanazawa and Mitsunobu Matsumoto and Kota Iwahori and Atsunari Kawashima and Akiko Morimoto-Okazawa and Hiroyoshi Nishikawa and Mikio Oka and Linda Pan and Ralph Venhaus and Eiichi Nakayama and Masaki Mori and Yuichiro Doki and Hisashi Wada",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/CJI.0000000000000162",
language = "English",
volume = "40",
pages = "140--147",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - NY-ESO-1 Protein Cancer Vaccine with Poly-ICLC and OK-432

T2 - Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC

AU - Takeoka, Tomohira

AU - Nagase, Hirotsugu

AU - Kurose, Koji

AU - Ohue, Yoshihiro

AU - Yamasaki, Makoto

AU - Takiguchi, Shuji

AU - Sato, Eiichi

AU - Isobe, Midori

AU - Kanazawa, Takayuki

AU - Matsumoto, Mitsunobu

AU - Iwahori, Kota

AU - Kawashima, Atsunari

AU - Morimoto-Okazawa, Akiko

AU - Nishikawa, Hiroyoshi

AU - Oka, Mikio

AU - Pan, Linda

AU - Venhaus, Ralph

AU - Nakayama, Eiichi

AU - Mori, Masaki

AU - Doki, Yuichiro

AU - Wada, Hisashi

PY - 2017/1/1

Y1 - 2017/1/1

N2 - We conducted a clinical trial of a cancer vaccine using NY-ESO-1 protein with polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose (poly-ICLC) and/or OK-432 against solid tumors. A total of 15 patients were sequentially enrolled in 4 cohorts. Patients in cohort 1 received NY-ESO-1 protein; cohort 2a received NY-ESO-1 protein+OK-432; cohort 2b received NY-ESO-1 protein+poly-ICLC; cohort 3 received NY-ESO-1 protein+OK-432+poly-ICLC with Montanide ISA-51. The endpoints of this trial were safety, NY-ESO-1 immune responses, and clinical response. Vaccine-related adverse events observed were fever and injection-site reaction (grade 1). Two patients showed stable disease after vaccination. NY-ESO-1 antibodies were observed in 4 patients at the baseline (sero-positive) and augmented in all patients after vaccination. Eleven patients showed a conversion of negative antibody responses at baseline to positive after vaccination (seroconversion). The seroconversions were observed in all 11 sero-negative patients by the fourth immunization; in particular, it was observed by the second immunization in patients with poly-ICLC, and these induced antibody responses were stronger than those in patients immunized without poly-ICLC. The number of NY-ESO-1-specific interferon (IFN)γ-producing T cells was increased in patients immunized with poly-ICLC and/or OK-432, and furthermore, the increase of IFNγ-producing CD8 T cells in patients immunized with poly-ICLC was significantly higher than that in patients without poly-ICLC. Nonspecific activations of T-cell or antigen presenting cells were not observed. Our present study showed that poly-ICLC is a promising adjuvant for cancer vaccines.

AB - We conducted a clinical trial of a cancer vaccine using NY-ESO-1 protein with polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose (poly-ICLC) and/or OK-432 against solid tumors. A total of 15 patients were sequentially enrolled in 4 cohorts. Patients in cohort 1 received NY-ESO-1 protein; cohort 2a received NY-ESO-1 protein+OK-432; cohort 2b received NY-ESO-1 protein+poly-ICLC; cohort 3 received NY-ESO-1 protein+OK-432+poly-ICLC with Montanide ISA-51. The endpoints of this trial were safety, NY-ESO-1 immune responses, and clinical response. Vaccine-related adverse events observed were fever and injection-site reaction (grade 1). Two patients showed stable disease after vaccination. NY-ESO-1 antibodies were observed in 4 patients at the baseline (sero-positive) and augmented in all patients after vaccination. Eleven patients showed a conversion of negative antibody responses at baseline to positive after vaccination (seroconversion). The seroconversions were observed in all 11 sero-negative patients by the fourth immunization; in particular, it was observed by the second immunization in patients with poly-ICLC, and these induced antibody responses were stronger than those in patients immunized without poly-ICLC. The number of NY-ESO-1-specific interferon (IFN)γ-producing T cells was increased in patients immunized with poly-ICLC and/or OK-432, and furthermore, the increase of IFNγ-producing CD8 T cells in patients immunized with poly-ICLC was significantly higher than that in patients without poly-ICLC. Nonspecific activations of T-cell or antigen presenting cells were not observed. Our present study showed that poly-ICLC is a promising adjuvant for cancer vaccines.

UR - http://www.scopus.com/inward/record.url?scp=85016070544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016070544&partnerID=8YFLogxK

U2 - 10.1097/CJI.0000000000000162

DO - 10.1097/CJI.0000000000000162

M3 - Article

AN - SCOPUS:85016070544

VL - 40

SP - 140

EP - 147

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 4

ER -